Jose Wiley

Jose Wiley

Auto-generated profile, based on publicly available information

Jose Wiley

Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Cardiovascular Pathology
Verified
Journal Article
Closed access
KPK-Raman Purushothaman
K-Raman Purushothaman
PKPrakash Krishnan
Prakash Krishnan
MPMeerarani Purushothaman
Meerarani Purushothaman
JWJose Wiley
Jose Wiley
CACarlos L. Alviar
Carlos L. Alviar
PMPedro R. Moreno
Pedro R. Moreno

1 December 2018 in Vascular
Verified
Journal Article
Closed access
WOWilman Olmedo
Wilman Olmedo
PVPedro A Villablanca
Pedro A Villablanca
CSCristina Sanina
Cristina Sanina
JWJonathan Walker
Jonathan Walker
MWMichael Weinreich
Michael Weinreich
JWJose Wiley
Jose Wiley
Background: Bivalirudin may be an effective alternative anticoagulant to heparin for use in percutaneous peripheral interventions. We aimed to compare the safety and efficacy of bivalirudin versus heparin as the procedural anticoagulant agent in patients undergoing percutaneous peripheral intervention. Methods: For this meta-analysis and systematic review, we conducted a search in PubMed, Medline, Embase, and Cochrane for all the clinical studies in which bivalirudin was compared to heparin as the procedural anticoagulant in percutaneous peripheral interventions. Outcomes studied included all-cause mortality, all-bleeding, major and minor bleeding, and access site complications. Results: Eleven studies were included in the analysis, totaling 20,137 patients. There was a significant difference favoring bivalirudin over heparin for all-cause mortality (risk ratio 0.58, 95% CI 0.39–0.87), all-bleeding (risk ratio 0.62, 95% CI 0.50–0.78), major bleeding (risk ratio 0.61, 95% CI 0.39–0.96), minor bleeding (risk ratio 0.66, 95% CI 0.47–0.92), and access site complications (risk ratio 0.66, 95% CI 0.51–0.84). There was no significant difference in peri-procedural need for blood transfusions (risk ratio 0.79, 95% CI 0.57–1.08), myocardial infarction (risk ratio 0.87, 95% CI 0.59–1.28), stroke (risk ratio 0.77, 95% CI 0.59–1.01), intracranial bleeding (risk ratio 0.77, 95% CI 0.29–2.02), or amputations (OR 0.75, 95% CI 0.53–1.05). Conclusion: Our meta-analysis suggests that bivalirudin use for percutaneous peripheral interventions is associated with lower all-cause mortality, bleeding, and access site complications as compared to heparin. Further large randomized trials are needed to confirm the current results.

1 August 2017 in Coronary Artery Disease
Verified
Journal Article
Closed access
PDF file
PVPedro A. Villablanca
Pedro A. Villablanca
DHDavid Holmes
David Holmes
DMDivyanshu Mohananey
Divyanshu Mohananey
DBDavid F. Briceno
David F. Briceno
INIván J. Núñez-Gil
Iván J. Núñez-Gil
FMFarouk Mookadam
Farouk Mookadam
We carried out a meta-analysis summarizing the efficacy and safety of direct factor Xa inhibitor (DXI) in patients receiving guideline-based antiplatelet therapy (GBAT) after an acute coronary syndrome. Randomized-controlled trials have shown that the addition of a DXI to GBAT after acute coronary syndrome can reduce ischemic events, the trade-off being an increase in major bleeding complications. PubMed, Central, Embase, The Cochrane Register, Google Scholar databases, and the scientific session abstracts were searched for eligible randomized trials from 1 January 1990 through 31 December 2016. Nine randomized-controlled trials were included in this meta-analysis enrolling a total of 45651 patients. There was a significant reduction in major adverse cardiovascular events with DXIs/GBAT compared with GBAT alone [odds ratio (OR): 0.88; 95% confidence interval (CI): 0.82–0.94, number needed to treat=52]. There were also significant reductions in two individual components of major adverse cardiovascular events: myocardial infarction (OR: 0.89; 95% CI: 0.81–0.98) and stent thrombosis (OR: 0.73; 95% CI: 0.59–0.90), favoring the DXI/GBAT group. There was an increased risk of major bleeding (OR: 2.51; 95% CI: 1.82–3.46) and intracranial hemorrhage (OR: 3.47; 95% CI: 1.76–6.86) compared with GBAT. In acute coronary syndromes, the addition of a DXI to GBAT results in a significant reduction of major adverse cardiovascular events, myocardial infarction, and stent thrombosis, offset by an increased risk of bleeding.

1 October 2017 in JACC
Verified
Journal Article
Closed access
WOWilman Olmedo
Wilman Olmedo
PVPedro Villablanca
Pedro Villablanca
MWMichael Weinreich
Michael Weinreich
TGTanush Gupta
Tanush Gupta
DMDivyanshu Mohananey
Divyanshu Mohananey
JWJose Wiley
Jose Wiley

1 October 2017 in JACC
Verified
Journal Article
Closed access
PVPedro Villablanca
Pedro Villablanca
WOWilman Olmedo
Wilman Olmedo
MWMichael Weinreich
Michael Weinreich
DMDivyanshu Mohananey
Divyanshu Mohananey
TGTanush Gupta
Tanush Gupta
JWJose Wiley
Jose Wiley

1 November 2016 in JACC
Verified
Journal Article
Closed access
PVPedro Villablanca
Pedro Villablanca
MMMohammed Makkiya
Mohammed Makkiya
DMDivyanshu Mohananey
Divyanshu Mohananey
ALAgata Leśniak-Sobelga
Agata Leśniak-Sobelga
RARasha Al-Bawardy
Rasha Al-Bawardy
DBDavid Briceno
David Briceno